Wealth Enhancement Advisory Services LLC Raises Stock Position in Encompass Health Co. (NYSE:EHC)

Wealth Enhancement Advisory Services LLC boosted its position in Encompass Health Co. (NYSE:EHC - Free Report) by 46.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,204 shares of the company's stock after buying an additional 6,053 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Encompass Health were worth $1,774,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Colonial Trust Co SC acquired a new stake in Encompass Health in the 4th quarter valued at approximately $29,000. Transce3nd LLC acquired a new stake in Encompass Health in the 4th quarter valued at approximately $40,000. CBIZ Investment Advisory Services LLC raised its position in Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock valued at $42,000 after buying an additional 127 shares during the last quarter. V Square Quantitative Management LLC raised its position in Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock valued at $54,000 after buying an additional 177 shares during the last quarter. Finally, Signaturefd LLC raised its position in Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company's stock valued at $65,000 after buying an additional 125 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

Insider Transactions at Encompass Health

In other news, insider Elissa Joy Charbonneau sold 4,279 shares of the business's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the sale, the insider now directly owns 11,958 shares of the company's stock, valued at $1,394,422.38. The trade was a 26.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of the business's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the sale, the executive vice president now owns 79,710 shares of the company's stock, valued at approximately $9,149,910.90. This represents a 11.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 132,663 shares of company stock worth $16,034,082. Company insiders own 2.00% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on EHC. Royal Bank of Canada lifted their target price on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Stephens raised Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price target on the stock in a research report on Thursday, June 5th. Wall Street Zen lowered Encompass Health from a "strong-buy" rating to a "buy" rating in a research report on Friday. Barclays boosted their price target on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, Truist Financial reaffirmed a "buy" rating and set a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $127.00.

Encompass Health Stock Down 0.9%

NYSE:EHC traded down $1.11 on Tuesday, hitting $119.19. The stock had a trading volume of 604,957 shares, compared to its average volume of 701,336. The business's fifty day moving average is $112.67 and its 200 day moving average is $103.04. The company has a market cap of $12.01 billion, a PE ratio of 26.72, a P/E/G ratio of 2.31 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 52 week low of $82.74 and a 52 week high of $123.13.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same period last year, the business posted $1.12 earnings per share. Encompass Health's revenue was up 10.6% on a year-over-year basis. On average, equities research analysts expect that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a dividend of $0.17 per share. The ex-dividend date is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.57%. Encompass Health's payout ratio is 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.